Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

Robert J. Kreitman, Constance M. Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Ira Pastan

Blood (2024) 144 (Supplement 1): 6791.

https://doi.org/10.1182/blood-2024-199569

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Robert J. Kreitman, Hao-Wei Wang, Dana I. Delgado Colon, Hong Zhou, Evgeny Arons, Mark Raffeld, Liqiang Xi, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Constance M. Yuan

Blood (2024) 144 (Supplement 1): 863.

https://doi.org/10.1182/blood-2024-202793

Published: 2024

Journal Articles

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Evgeny Arons, Chin-Hsien Tai, Suraj Joshi, Yuelin Liu, Chi-ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman, Christopher C. Oakes, Seema A Bhat, Michael R. Grever, Kerry A. Rogers, Hao-Wei Wang, Constance M. Yuan, Cenk Sahinalp, Robert J. Kreitman

Blood (2024) 144 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2024-204016

Published: 2024

Journal Articles

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Chingiz Underbayev, MD PhD, Inhye E Ahn, MD, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, MD PhD, Liqiang Xi, MD, Mark Raffeld, MD, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 1287.

https://doi.org/10.1182/blood-2019-127364

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Recurrent somatic JAK3 mutations in NK-cell enteropathy

Wenbin Xiao, Gaurav K. Gupta, Jinjuan Yao, Yoon J. Jang, Liqiang Xi, Jeeyeon Baik, Allison Sigler, Anita Kumar, Alison J. Moskowitz, Maria E. Arcila, Mark Raffeld, Stefania Pittaluga, Ahmet Dogan, Elaine S. Jaffe

Blood (2019) 134 (12): 986–991.

https://doi.org/10.1182/blood.2019001443

Published: 2019

Includes: Supplemental data

Journal Articles

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood (2017) 129 (11): 1469–1479.

https://doi.org/10.1182/blood-2016-06-719294

Published: 2017

Includes: Supplemental data

Journal Articles

Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea

Chi A. Ma, Liqiang Xi, Brian Cauff, Adam DeZure, Alexandra F. Freeman, Sophie Hambleton, Gary Kleiner, T. Ronan Leahy, Maureen O’Sullivan, Michelle Makiya, Grainne O’Regan, Stefania Pittaluga, Julie Niemela, Jennifer Stoddard, Sergio D. Rosenzweig, Mark Raffeld, Amy D. Klion, Joshua D. Milner

Blood (2017) 129 (5): 650–653.

https://doi.org/10.1182/blood-2016-09-737817

Published: 2017

Includes: Supplemental data

Journal Articles

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

Alina Nicolae, Stefania Pittaluga, Shahed Abdullah, Seth M. Steinberg, Thu Anh Pham, Theresa Davies-Hill, Liqiang Xi, Mark Raffeld, Elaine S. Jaffe

Blood (2015) 126 (7): 863–872.

https://doi.org/10.1182/blood-2015-02-630632

Published: 2015

Includes: Supplemental data

Journal Articles

Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome

Amy D. Klion, Rojelio Mejia, Edward W. Cowen, Kennichi C. Dowdell, Kieron Dunleavy, Gary A. Fahle, Nicole Holland-Thomas, Irina Maric, Stefania Pittaluga, Mark Raffeld, Carlo Santos, Maryalice Stetler-Stevenson, Tammy Krogmann, Amber N. Shatzer, Siu-Ping Turk, Yuzhi Yin, Liqiang Xi, Calman Prussin, Jeffrey I. Cohen

Blood (2013) 121 (12): 2364–2366.

https://doi.org/10.1182/blood-2012-12-472720

Published: 2013

Journal Articles

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Blood (2012) 120 (21): 732.

https://doi.org/10.1182/blood.V120.21.732.732

Published: 2012

Journal Articles

Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation

Liqiang Xi, Evgeny Arons, Winnifred Navarro, Katherine R. Calvo, Maryalice Stetler-Stevenson, Mark Raffeld, Robert J. Kreitman

Blood (2012) 119 (14): 3330–3332.

https://doi.org/10.1182/blood-2011-09-379339

Published: 2012

Includes: Supplemental data

Journal Articles

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Robert J. Kreitman, MD, Liqiang Xi, MD, Winnifred Navarro, BS, Maryalice Stetler-Stevenson, MD, PhD, Evgeny Arons, PhD, Mark Raffeld, MD

Blood (2011) 118 (21): 931.

https://doi.org/10.1182/blood.V118.21.931.931

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

NARROW

Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab Pasudotox

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Recurrent somatic JAK3 mutations in NK-cell enteropathy

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment

Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only